Ipamorelin
Product Quick Detail
- Minimum Order
- 10
- Place Of Origin
- China
- Packaging
- vial
- Delivery
- 15 Days
Specifications
Product Details
Basic Info.
Model NO.:170851-70-4
Synonyms:Ipomarelin;Ipamorelin Acetate
Assay:99%
Delivery Mode:EMS, DHL, etc.
Delivery Time:Within 24 Hours After Payment
Related:Melanotan1, Ipamorelin, PT-141
Export Markets:Global
Additional Info.
Trademark:Saichuang
Packing:2mg/Vial, 10vial/Kit
Standard:ISO9001
Origin:China
HS Code:29224999
Production Capacity:100kg/Month
Product Description
High Quality Peptide Powder Ipamorelin for Weight Loss (2mg/vial)
1.Ipamorelin quick detail:
Ipamorelin
Synonyms:Ipomarelin;Ipamorelin acetate;Aib-his-d-2-nal-d-phe-lys-nh2
Cas:170851-70-4
Mf:C38h49n9o5
Mw:711.863
Product categories:Peptides
2.Ipamorelin specifications:5mg/vial, 10vial/box
Appearance :White powder
Water content(karl fischer) :≤5.0%
Acetate content(by hplc) :≤15.0%
Amino acid composition :±10% of theoretical
Purity (by hplc) :≥98.0%
Single impurity(by hplc) :≤1.0%
Peptide content(by %n) :≥80%
Assay(by anhydrous, acetic acid-free ) :95.0~105.0%
Bacterial endotoxins :≤5eu/mg
Packing:Plastic vial(dedicated for peptide packing) or glass vial, quantity according to customer's detail requirement.
Storage:A cool(2~8 oc) & dry place protected from light, keep package close when not in use.
The Ipamorelin Releasing Peptide Comparison
Ipamorelin is a 3rd generation GHRP behind GHRP-6 and GHRP-2. Ipamorelin has very similar characteristics of GHRP-2: does not have ghrelin's lipogenic properties and does not promote hunger.
Ipamorelin acts synergistically when applied during a Growth Hormone Releasing Hormone (GHRH) pulse or when it is administered along with a GHRH or an analog such as Sermorelin or Modified GRF 1-29
(growth releasing factor, aminos 1-29). The synergy comes both due to the suppression of somatostatin and the fact that ipamorelin increases GH release per-somatotrope, while GHRH increases the
number of somatotropes releasing GH. On the other hand, Ipamorelin is similar to GHRP-6 because they both release GH at a very similar strength minus the side effects that of GHRP-6. Both GHRP-6
and GHRP-2 cause a release and an increase in cortisol and prolactin levels, however Ipamorelin only selectively releases GH at any dose. Ipamorelin shares similar functionality to Hexarelin and
compared to other peptides, it is a much more stable form of ghrelin and has longer half-life periods of at least two hours long and causes secondary effect by making neurons to become excited.
Studies Related to Ipamorelin
Ipamorelin has been shown to be both highly potent and very selective in vivo and vitro situations, and has also demonstrated good safety and tolerability in human clinical studies. Research has
shown that Ipamorelin is growth hormone specific which means that the pituitary hormones such as cortisol are unaffected. In one study, it was found that young female adult rats had increased bone
mass due to 12 weeks of treatment with ipamorelin. This peptide compared to other Growth Hormone Releasing Peptides ensures the benefits without having to deal with possible negative side effects.
Description:
Ipamorelinis a fascinating new muscle building discovery that is getting a lot of attention in the bodybuilding world. Like the GHRP-6 peptide (growth hormone releasing hexapeptide), it is a
synthetic peptide that has powerful Growth Hormone releasing properties. And these GH releasing properties are what is of interest to athletes and bodybuilders since they can make a tremendous
difference in the amount of muscle you can grow and how quickly you burn fat.
Application :
Ipamorelin is an interesting peptide taken 300mcg twice daily or you could lower the dose for 3 times daily, side effects are head rushs, I would recommend taking this 30 minutes before workout
,with gear, Ipamorelin is a new and potent synthetic pentapeptide which has distinct and specific growth hormone releasing properties. With the objective of investigating the effects on
longitudinal bone growth rate , body weight , and growth hormone release, Ipamorelin in different doses (0, 18, 90 and 450 μg/day) was injected three times daily for 15 days to test subjects,
After intravital Tetracycline labelling on days 0, 6, and 13, LGR was determined by measuring the distance between the respective fluorescent bands in the proximal tibia metaphysis. Ipamorelin
dose-dependently increased LGR from 42 μm/day in the vehicle group to 44, 50, and 52 μm/day in the treatment groups . There was also a pronounced and dose-dependent effect on body weight gain.
The treatment did not affect total IGF-I levels, or serum markers of bone formation and resorption. The number of tartrate-resistant acid phosphatase-positive multinuclear cells in the metaphysis
of the tibia did not change significantly with treatment.
- Country:
- Business Type:
- Market:
- Founded Year:
- Address:
- Contact:Jackson Van
